AIM Other Operating Expenses from 2010 to 2024
| AIM Stock | USD 0.23 0.02 9.52% |
Other Operating Expenses | First Reported 1995-10-31 | Previous Quarter 3.7 M | Current Value 4.5 M | Quarterly Volatility 1.6 M |
Check AIM ImmunoTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AIM ImmunoTech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 226.1 K, Total Revenue of 386.8 K or Gross Profit of 168 K, as well as many indicators such as Price To Sales Ratio of 101, Dividend Yield of 0.0 or PTB Ratio of 1.98. AIM financial statements analysis is a perfect complement when working with AIM ImmunoTech Valuation or Volatility modules.
AIM | Other Operating Expenses |
Latest AIM ImmunoTech's Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of AIM ImmunoTech over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AIM ImmunoTech. It is also known as AIM ImmunoTech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. AIM ImmunoTech's Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AIM ImmunoTech's overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
AIM Other Operating Expenses Regression Statistics
| Arithmetic Mean | 17,391,993 | |
| Geometric Mean | 15,771,856 | |
| Coefficient Of Variation | 43.31 | |
| Mean Deviation | 5,172,658 | |
| Median | 16,783,000 | |
| Standard Deviation | 7,531,913 | |
| Sample Variance | 56.7T | |
| Range | 29.7M | |
| R-Value | 0.61 | |
| Mean Square Error | 38.3T | |
| R-Squared | 0.37 | |
| Significance | 0.02 | |
| Slope | 1,029,719 | |
| Total Sum of Squares | 794.2T |
AIM Other Operating Expenses History
About AIM ImmunoTech Financial Statements
AIM ImmunoTech investors utilize fundamental indicators, such as Other Operating Expenses, to predict how AIM Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 32.1 M | 33.7 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of AIM ImmunoTech Correlation against competitors. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.48) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.